Aclaris Therapeutics (NASDAQ:ACRS – Free Report) had its price objective lowered by Canaccord Genuity Group from $13.00 to $12.00 in a research note released on Tuesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.
Other analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a research report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Craig Hallum set a $9.00 target price on Aclaris Therapeutics in a research report on Wednesday, October 28th. Wedbush downgraded Aclaris Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $3.00 in a research note on Tuesday. Finally, Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aclaris Therapeutics has an average rating of “Buy” and a consensus target price of $10.67.
Read Our Latest Stock Analysis on Aclaris Therapeutics
Aclaris Therapeutics Price Performance
Shares of NASDAQ:ACRS opened at $3.50 on Tuesday. Aclaris Therapeutics has a 1 year low of $2.34 and a 1 year high of $6.60. The company’s 50 day simple moving average is $4.25 and its 200 day simple moving average is $4.53.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. Equities analysts anticipate that Aclaris Therapeutics will post -0.56 EPS for the current year.
Institutional Trading of Aclaris Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at $53,096,000. Rock Springs Capital Management LP increased its holdings in Aclaris Therapeutics by 0.4% in the 1st quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock worth $16,772,000 after purchasing an additional 18,909 shares in the last quarter. Braidwell LP increased its holdings in Aclaris Therapeutics by 26.1% in the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after purchasing an additional 443,232 shares in the last quarter. Kalehua Capital Management LLC acquired a new position in Aclaris Therapeutics in the 1st quarter worth about $6,871,000. Finally, Palo Alto Investors LP bought a new position in Aclaris Therapeutics in the second quarter valued at about $8,535,045. Institutional investors own 98.34% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
Further Reading
- Five stocks we like better than Aclaris Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
